The CRA Board meets at least twice yearly in conjunction with the NCCTG Spring and Fall Group meetings. The CRA Board is comprised of nine members elected by all NCCTG CRAs and Operations Office personnel. Seven of these board members are CRAs from NCCTG member institutions and two board members are elected from NCCTG Operations Office personnel. Board members severe two-year terms and may serve an unlimited number of terms. Two measures are written into the bylaws of the Board to ensue the stability and continuity of the CRA Board. To help provide experienced leadership, the Vice-chair is elected from among the Board members and serves in that capacity until moving into the Chair position in the subsequent term. To improve interest and activity, elections of the two members from the NCCTG Operations Office are staggered; as the Operations office staff participates and facilitates many of the educational efforts of t he Board, this ensures that there will always be an experienced Board member from the Operations Office. The current CRA Board officers, begin their terms in the fall of 199. They are Stefanie A. Steiner, CCRA. Chair; Lynda Dupuis, CCRA, Vice-Chair; Laura Mahacek, RN, OCN, Secretary.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA025224-23
Application #
6563782
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-01-11
Project End
2002-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
23
Fiscal Year
2002
Total Cost
$78,870
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
McWilliams, Robert R; Allred, Jacob B; Slostad, Jessica A et al. (2018) NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab?±?everolimus for metastatic melanoma. Cancer 124:537-545
Chumsri, Saranya; Sperinde, Jeff; Liu, Heshan et al. (2018) High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin Cancer Res 24:3053-3058
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Feliciano, Josephine L; Le-Rademacher, Jennifer G; Gajra, Ajeet et al. (2018) Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). J Geriatr Oncol 9:501-506
Schiff, David; Jaeckle, Kurt A; Anderson, S Keith et al. (2018) Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. Cancer 124:1455-1463
Foster, Jared C; Le-Rademacher, Jennifer G; Feliciano, Josephine L et al. (2017) Comparative ""nocebo effects"" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort. Cancer 123:4193-4198
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Witzig, T E; LaPlant, B; Habermann, T M et al. (2017) High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance). Blood Cancer J 7:e576
Brown, Paul D; Ballman, Karla V; Cerhan, Jane H et al. (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1049-1060

Showing the most recent 10 out of 718 publications